Dr. Ali-Fehmi practices surgical pathology, gynecologic oncology pathology, breast pathology, and molecular diagnosis. She has over 10 years of clinical experience in general surgical pathology with a subspecialty in gynecologic oncology pathology, particularly in the area of ovarian, uterine and cervical malignancies. Her consultation expertise is focused in ovarian and uterine pathology. She serves as the Co-Director of the Gynecology Oncology Multidisciplinary Conference at the Karmanos Cancer Institute.
Tumor markers of ovarian cancer, endometrial cancer and breast cancer.
Dr. Ali-Fehmi has been interested in the histopathology and biological characteristics of ovarian and uterine malignancy. Dr. Ali has been actively involved in multiple clinical trials as an expert pathologist. Dr. Ali-Fehmi is also interested in genetic changes and expression profiling of markers for the diagnosis and prognosis of ovarian carcinoma. Dr. Ali-Fehmi is currently an investigator on several funded research projects that involve underlying molecular mechanisms of ovarian tumor progression and metastasis.
(1995-1998) Anatomic Pathology
Case Western Reserve University, University Hospitals of Cleveland
Cleveland, Ohio, USA
Damascus University School of Medicine
Fellowship in Obstetric-Gynecological Pathology (1998-2000)
Detroit Medical Center - Hutzel
Detroit, MI, USA
Fellowship in Cytopathology (2000 to 2001)
Detroit Medical Center - Hutzel Hospital
Detroit, MI, USA
Board Certified in Anatomic Pathology
Director of the Endocrine Pathophysiology unit in the medical school second year course
Lab instructor for the medical school second year Pathophysiology and Pathophysiology unit
Teaching and mentoring the pathology residents at Harper University Hospital.
Director of WSU Department of Pathology Annual Course (a full day CME program),
Director of Pathology Education, GYN Pathology Translational Research, Department of OB/GYN
Mentor of the Gynecology Oncology fellows
1. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, and Munkarah AR, 2003, The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma, Cancer, 98: 1423-9.
2. Ali-Fehmi R, Qureshi F, Lawrence WD, and Jacques S, 2004, Apoptosis, proliferation, and expression of P53 and BCL-2 in endocervical intraepithelial glandular lesions and invasive endocervical adenocarcinoma, Int J Gynecol Pathol, 2: 1-6.
3. Ali-Fehmi R, Khalifeh I, Bandyopadhyay S, Lawrence WD, Silva EG, Liao J, Sarkar F, and Munkarah AR, 2006, Patterns of loss of hetrozygosity (LOH) at 10q123.3 and microsatellite instability (MSI) in ovarian endometriosis, atypical endometriosis and epithelial carcinoma arising in a background of endometriosis, Int J Gynecol Pathol, 25: 223-9.
4. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, and Tainsky MA, 2006, Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays, Cancer Res, 66: 1181-90.
5. Arabi H, Guan H, Kumar S, Cote M, Bandyopadhyay S, Bryant C, Shah J, Abdul-Karim FW, Munkarah AR, and Ali-Fehmi R, 2009, Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma, Gynecol Oncol, 113: 153-8.